Rx Product News

Pharmacy Times, March 2014 Mental Health, Volume 80, Issue 3

Our round-up of the latest Rx products.

Auxilium Pharmaceuticals, Inc

Indication: Stendra (avanafil) is a phosphodiesterase 5 inhibitor indicated for the treatment of erectile dysfunction. The recommended starting dose is 100 mg. The dose may be increased to a maximum of 200 mg or decreased to 50 mg. The maximum recommended dosing frequency is once per day. Stendra should be taken as needed approximately 30 minutes before sexual activity.

Dosage Form: Tablets: 50, 100, and 200 mg

For More Information: www.stendra.com

Breo ElliptaMarketed by: GlaxoSmithKline and Theravance, Inc

Indication: Breo Ellipta (fluticasone furoate and vilanterol inhalation powder), which received FDA approval in May 2013, is now available to pharmacies throughout the United States. Breo Ellipta is indicated for long-term maintenance treatment of airflow obstruction and for reducing exacerbations in patients with chronic obstructive pulmonary disease. The recommended dose is 1 oral inhalation (100 mcg/25 mcg) once daily.

Dosage Form: Inhalation powder (fluticasone furoate/vilanterol): 100 mcg/25 mcg

For More Information: http://phrmcyt.ms/Mzyvep

GazyvaMarketed by: Genentech, Inc

Indication: The FDA has approved Gazyva (obinutuzumab) for use in combination with chlorambucil to treat patients with previously untreated chronic lymphocytic leukemia. Gazyva should be diluted and administered as an intravenous (IV) infusion—not as an IV push or bolus. The recommended dose for 6 cycles (28-day cycles) is 100 mg on day 1, cycle 1; 900 mg on day 2, cycle 1; 1000 mg on days 8 and 15 of cycle 1; and 1000 mg on day 1 of cycles 2 through 6.

Dosage Form: Single-use vial: 1000 mg/40 mL (25 mg/mL)

For More Information: www.gazyva.com

CopaxoneMarketed by: Teva Pharmaceutical Industries Ltd

Indication: The FDA has approved a supplemental new drug application for 3-times-a-week Copaxone (glatiramer acetate injection) 40 mg/mL for the treatment of patients with relapsing forms of multiple sclerosis (MS). This new formulation will allow patients with relapsing MS to have a less frequent subcutaneous dosing regimen (ie, 3 times per week). Daily Copaxone 20 mg/mL for subcutaneous injection will continue to be available.

Dosage Form: Subcutaneous injection: 20 and 40 mg/mL

For More Information: www.copaxone.com/40-mg-injection